Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.
Kousuke UedaShigetaka SuekaneHirofumi KuroseNaoki ItoNaoyuki OgasawaraTasuku HiroshigeKatsuaki ChikuiKazuhisa EjimaKeiichiro UemuraMakoto NakiriKiyoaki NishiharaTsukasa IgawaPublished in: Japanese journal of clinical oncology (2022)
Patients with advanced renal cell carcinoma with immune-related adverse events had superior clinical outcomes of nivolumab plus ipilimumab treatment than those without immune-related adverse events. Skin immune-related adverse events may be effective biomarkers in patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab.